Shire PLC (NASDAQ:SHPG)‘s stock had its “overweight” rating reiterated by investment analysts at JPMorgan Chase & Co. in a research note issued to investors on Monday.
A number of other equities analysts also recently issued reports on SHPG. Piper Jaffray Cos. set a $201.00 price target on shares of Shire PLC and gave the company a “hold” rating in a report on Saturday, October 1st. Leerink Swann reiterated a “buy” rating on shares of Shire PLC in a report on Saturday, October 1st. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a report on Wednesday, August 3rd. RBC Capital Markets reiterated an “outperform” rating on shares of Shire PLC in a report on Wednesday, August 3rd. Finally, Zacks Investment Research upgraded shares of Shire PLC from a “sell” rating to a “hold” rating in a report on Thursday, August 4th. Five investment analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. Shire PLC currently has an average rating of “Buy” and a consensus target price of $228.15.
Shire PLC (NASDAQ:SHPG) opened at 190.70 on Monday. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32. The firm has a market capitalization of $56.80 billion, a price-to-earnings ratio of 39.63 and a beta of 1.16. The company’s 50-day moving average is $194.55 and its 200-day moving average is $188.26.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.35. The firm earned $2.43 million during the quarter, compared to analysts’ expectations of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. Shire PLC’s quarterly revenue was up 55.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.63 EPS. Equities analysts predict that Shire PLC will post $12.92 earnings per share for the current year.
The firm also recently declared a dividend, which was paid on Friday, October 7th. Shareholders of record on Friday, September 9th were given a dividend of $0.139 per share. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is 15.63%.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in shares of Shire PLC by 12.6% in the first quarter. Renaissance Technologies LLC now owns 313,212 shares of the biopharmaceutical company’s stock worth $53,841,000 after buying an additional 35,100 shares during the period. Reynolds Capital Management LLC purchased a new stake in Shire PLC during the first quarter worth about $206,000. OLD Mission Capital LLC purchased a new stake in Shire PLC during the first quarter worth about $28,179,000. Pictet Asset Management Ltd. raised its stake in Shire PLC by 18.6% in the first quarter. Pictet Asset Management Ltd. now owns 147,339 shares of the biopharmaceutical company’s stock worth $23,001,000 after buying an additional 23,105 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in Shire PLC during the first quarter worth about $3,111,000. 24.30% of the stock is currently owned by hedge funds and other institutional investors.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.